[Sinopharm Hyundai: subsidiary ceftriaxone sodium for injection passes generic drug consistency evaluation] June 15, Sinopharm Hyundai announcement, the company's wholly-owned subsidiary Sinopharmaceutical Group Weiqida Pharmaceutical Co., Ltd. received a notice of approval for Supplementary Drug Application issued by the State Drug Administration, approving ceftriaxone sodium for injection (1.0g) to pass the consistency evaluation of the quality and efficacy of generic drugs. The company announced on the same day that the board of directors recently received a written resignation report from Mr. Hao Chaofeng, the company's chief financial officer. Mr. Hao Chaofeng applied to resign as chief financial officer for personal reasons. After resigning, Mr. Hao Chaofeng will not hold any position in the company.